The CRC occurrence and progression are commonly associated with 35%–45% mutation of oncogenic Kirsten Ras sarcoma viral oncogene homolog (Strand et al., 2019) and nearly 50% loss of p53-suppressor function (Huang et al., 2018). The gene discussed is TP53; the disease is colorectal carcinoma.